Investigational agents for rheumatoid arthritis.

Abstract

Agents ranging from simple analgesics to antiinflammatory drugs to powerful immunomodulators have been used for the treatment of rheumatoid arthritis with varying success. Despite the availability of agents that are believed to be "second line" or "disease modifying," many patients either do not respond adequately to available agents or must discontinue their use because of intolerable or dangerous adverse reactions. For this reason, researchers continue to search for more efficacious and less toxic agents for patients with rheumatoid arthritis. This article describes pharmaceutical agents currently under investigation for use in rheumatoid arthritis, including the antiinflammatory agents, zileuton and tenidap, and the immunosuppressive agents, leflunomide, mycophenolic acid (RS-61443), tacrolimus (FK-506), sirolimus (rapamycin), amiprilose (therafectin), cladribine (2- chlorodeoxyadenosine), and azaribine.

• Authors: P A Merkel, E N Letourneau, R P Polisson
• Journal: Rheumatic diseases clinics of North America (Rheum Dis Clin North Am) Vol. 21 Issue 3 Pg. 779-96 (Aug 1995) ISSN: 0889-857X [Print] United States
• PMID: 8619099 (Publication Type: Journal Article, Review)

Chemical References

• Anti-Inflammatory Agents
• Antirheumatic Agents
• Drugs, Investigational
• Immunosuppressive Agents

Topics

• Animals
• Anti-Inflammatory Agents (adverse effects, pharmacology, therapeutic use)
• Antirheumatic Agents (adverse effects, pharmacology, therapeutic use)
• Arthritis, Rheumatoid (drug therapy)
• Clinical Trials as Topic
• Drugs, Investigational (adverse effects, pharmacology, therapeutic use)
• Humans
• Immunosuppressive Agents (adverse effects, pharmacology, therapeutic use)
• Treatment Outcome